Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

por Gatell, Josep M, Morales-Ramirez, Javier O, Hagins, Debbie P, Thompson, Melanie, Keikawus, Arasteh, Hoffmann, Christian, Rugina, Sorin, Osiyemi, Olayemi, Escoriu, Simona, Dretler, Robin, Harvey, Charlotte, Xu, Xia, Teppler, Hedy
Publicado 2014